Radiotherapy-Activated Prodrug: Past, Present and Beyond
ACS Central Science · 27.08.2025 · 11 (8) · 1306-1320
DOI: 10.1021/acscentsci.5c00875 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift ACS Central Science, online erschienen am 16.07.2025. Verfasst von Changlun Wang und 2 weiteren Autor:innen. Beteiligte Einrichtung: Peking University-Tsinghua University Center for Life Sciences, Peking University, Beijing 100871, China. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 105 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Science and Technology of the People's Republic of China, Natural Science Foundation of Beijing Municipality, National Natural Science Foundation of China.
Abstract (Originalsprache)
Radiotherapy-activated prodrug (RAP) is defined as a type of prodrug that features low toxicity before activation, transforms into an active form upon ionizing radiation exposure, and exhibits targeted therapeutic effects within the irradiated area. In clinical practice, clear evidence demonstrates that the combination of radiotherapy and chemotherapy elicits a significant synergistic antitumor response, thereby enhancing patients' overall survival rates. As a novel therapeutic modality, RAP has recently emerged as an active area of scientific research. The primary mechanism of RAP involves utilizing the reactive species from water radiolysis under ionizing radiation to trigger controlled cleavage of covalent bonds, enabling the controlled release of active drugs. In this Outlook, we summarize the advancements in the field of RAP, encompassing the types of ionizing radiation, novel chemical structures, and diverse prodrug formats. In addition, we discuss the current challenges and future directions of this promising field.
Autor:innen und Institutionen
- Peking University-Tsinghua University Center for Life Sciences, Peking University, Beijing 100871, China.
- Beijing National Laboratory for Molecular Sciences, Radiochemistry and Radiation Chemistry Key Laboratory of Fundamental Science, Key Laboratory of Bioorganic Chemistry and Molecular Engineering of Ministry of Education…
- Changping Laboratory, Beijing 102206, China.
- Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), NMPA Key Laboratory for Research and Evaluation of Radiopharmaceuticals (National Medical Products Administration), Department…
ORCID-Profile: Zhibo Liu
Förderung
- Ministry of Science and Technology of the People's Republic of China
- Natural Science Foundation of Beijing Municipality
- National Natural Science Foundation of China
- Changping Laboratory
Zitieren
APA
Wang, C., Zhang, Z., & Liu, Z. (2025). Radiotherapy-Activated Prodrug: Past, Present and Beyond. ACS Central Science, 11(8), 1306-1320. https://doi.org/10.1021/acscentsci.5c00875
Vancouver
Wang C, Zhang Z, Liu Z. Radiotherapy-Activated Prodrug: Past, Present and Beyond. ACS Central Science. 2025;11(8):1306-1320. doi:10.1021/acscentsci.5c00875
BibTeX
@article{Wang2025,
author = {Wang, Changlun and Zhang, Zihang and Liu, Zhibo},
title = {Radiotherapy-Activated Prodrug: Past, Present and Beyond},
journal = {ACS Central Science},
year = {2025},
volume = {11},
number = {8},
pages = {1306--1320},
doi = {10.1021/acscentsci.5c00875}
}
EUVIMED